Table 1

Patient characteristics at first visit during second-year follow-up postdiagnosis

Number of patients165
Age57.3 (13.7)*
Female59%
Rheumatoid factor positive60%
Disease duration in months12.5 (11.8–13.2)†
DAS283.0 (1.1)*
PROM score32 (24)*
Receiving DMARD78% (Methotrexate)‡
Receiving biologic13% (Adalimumab)‡
  • *Mean (SD).

  • †Median (IQR).

  • ‡Most prevalent agent.

  • DAS28, Disease Activity Score 28-joint count; DMARD, disease-modifying antirheumatic drug; PROM score, patient-reported outcome measure score consisting of an equally weighted mean of visual analogue scales for general health, pain and disease activity.